Innovative Licensing and Access Pathway (ILAP) for medicines Guidance for applicants on applying to the ILAP From: Details The Innovative Licensing and Access Pathway (ILAP) aims to accelerate the time to market, facilitating patient access to medicines. These medicines include new chemical entities, biological medicines, new indications and repurposed medicines. The ILAP awards a new “innovative medicine” designation (Innovation Passport), utilises tools from a toolkit and a “Road Map” (Target Development Profile, TDP). The pathway brings together innovative approaches to support the safe, timely and efficient development of innovative products. Published 22 December 2020